organization · Reporting owner

CELGENE CORP /DE/

Disclosed activity across 7 companies

Tapewire entity: 15781
SEC CIK: 0000816284

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499	10% owner	November 12, 2019	November 14, 2019
Adynxx, Inc.ALQA · Entity 155807	10% owner	April 11, 2017	April 13, 2017
Jounce Therapeutics, Inc.JNCE · Entity 15754	10% owner	February 01, 2017	February 01, 2017
Juno Therapeutics, Inc.JUNO · Entity 168572	10% owner	March 05, 2018	March 06, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGIOS PHARMACEUTICALS, INC.

Report date November 12, 2019 · Filed November 14, 2019

Jointly reported with Celgene European Investment Co LLC, Celgene Switzerland LLC, Celgene Alpine Investment Co., LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,777,824	Reported balance After 2019-11-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-11-12 · Purchase · Acquired 403,225 · Balance 1,777,824
Common StockSEC Table I · non-derivative	IndirectSee footnote	624,575	Reported balance Holding disclosure · report date 2019-11-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 624,575 F1: Owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,010,926	Reported balance Holding disclosure · report date 2019-11-12 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 4,010,926 F2: Owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	708,333	Reported balance Holding disclosure · report date 2019-11-12 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 708,333 F3: Owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2: Owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F3: Owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Adynxx, Inc.

Report date April 11, 2017 · Filed April 13, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,342,377	Reported balance After 2017-04-11 transaction · row 1 1 source row Row 1 · 2017-04-11 · Other · Acquired 296,277 · Balance 7,342,377 F1: Pursuant to a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated February 27, 2017, with the Issuer, the Reporting Person purchased in a private placement (the "Private Placement") 4,000,000 shares of Common Stock at a purchase price of $0.50 per share (the "Per Share Purchase Price"). The Securities Purchase Agreement contains a "most-favored nation" provision that provides that if the Issuer, during 120 days from February 27, 2017, issues or sells any Common Stock or Common Stock equivalents reasonably believed to be more favorable in terms or conditions than the Private Placement, the Issuer must amend the terms of the Securities Purchase Agreement to give the Private Placement investors, including the Reporting Person, the benefit of such more favorable terms or conditions. F2: In accordance with this provision, effective as of April 11, 2017, following a public offering of Common Stock at a purchase price of $0.40 per share (the "Public Offering Price") on April 3, 2017, the Issuer adjusted the Per Share Purchase Price to the Public Offering Price, and is required to issue additional shares of Common Stock to the Private Placement investors, including the Reporting Person, which issuance is subject to stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market and certain side letter agreement, dated March 13, 2017, between the Issuer and the Reporting Person (the "Side Letter"). F3: Pursuant to the Securities Purchase Agreement and subject to the Side Letter, on April 11, 2017, the Issuer issued 296,277 shares of Common Stock to the Reporting Person (the "MFN Shares"), and will issue 703,723 additional shares of Common Stock to the Reporting Person if the Issuer obtains stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated February 27, 2017, with the Issuer, the Reporting Person purchased in a private placement (the "Private Placement") 4,000,000 shares of Common Stock at a purchase price of $0.50 per share (the "Per Share Purchase Price"). The Securities Purchase Agreement contains a "most-favored nation" provision that provides that if the Issuer, during 120 days from February 27, 2017, issues or sells any Common Stock or Common Stock equivalents reasonably believed to be more favorable in terms or conditions than the Private Placement, the Issuer must amend the terms of the Securities Purchase Agreement to give the Private Placement investors, including the Reporting Person, the benefit of such more favorable terms or conditions.

F2: In accordance with this provision, effective as of April 11, 2017, following a public offering of Common Stock at a purchase price of $0.40 per share (the "Public Offering Price") on April 3, 2017, the Issuer adjusted the Per Share Purchase Price to the Public Offering Price, and is required to issue additional shares of Common Stock to the Private Placement investors, including the Reporting Person, which issuance is subject to stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market and certain side letter agreement, dated March 13, 2017, between the Issuer and the Reporting Person (the "Side Letter").

F3: Pursuant to the Securities Purchase Agreement and subject to the Side Letter, on April 11, 2017, the Issuer issued 296,277 shares of Common Stock to the Reporting Person (the "MFN Shares"), and will issue 703,723 additional shares of Common Stock to the Reporting Person if the Issuer obtains stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market.

Jounce Therapeutics, Inc.

Report date February 01, 2017 · Filed February 01, 2017

Jointly reported with Celgene Switzerland LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,456,463	Last balance in matching sequence After 2017-02-01 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2017-02-01 · Conversion · Acquired 2,831,463 · Balance 2,831,463 F1: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F2: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Row 2 · 2017-02-01 · Purchase · Acquired 625,000 · Balance 3,456,463 F2: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Series B-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-02-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-01 · Conversion · Disposed 10,448,100 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F2: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date.

F2: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Juno Therapeutics, Inc.

Report date March 05, 2018 · Filed March 06, 2018

Jointly reported with Celgene Switzerland LLC, Blue Magpie Corp

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	11,109,160	Reported balance Holding disclosure · report date 2018-03-05 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 11,109,160 F1: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene").
Common StockSEC Table I · non-derivative	IndirectSee Footnote	88,118,707	Reported balance Holding disclosure · report date 2018-03-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 88,118,707 F2: These shares are owned directly by Blue Magpie Corporation, a wholly-owned subsidiary of Celgene.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene").

F2: These shares are owned directly by Blue Magpie Corporation, a wholly-owned subsidiary of Celgene.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACCELERON PHARMA INC

Report date July 09, 2020 · Filed July 13, 2020

Jointly reported with BRISTOL MYERS SQUIBB CO

Section 16 reporting ended · disclosed 2020-07-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,010,751	Reported balance After 2020-07-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-07-09 · Other · Acquired 38,979 · Balance 7,010,751 F1: This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the "Reporting Persons"). F2: These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities.
Common StockSEC Table I · non-derivative	Direct	7,008,510	Reported balance After 2020-07-09 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-07-09 · Sale · Disposed 2,241 · Balance 7,008,510 F3: On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares.
Option WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2020-07-09	Direct	0	Reported balance After 2020-07-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-09 · Other · Disposed 38,979 · Balance 0 F4: All of the shares are currently exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the "Reporting Persons").

F2: These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities.

F3: On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares.

F4: All of the shares are currently exercisable.

CRISPR Therapeutics AG

Report date November 03, 2017 · Filed December 07, 2017

Section 16 reporting ended · disclosed 2017-12-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,812,221	Reported balance After 2017-11-03 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-11-03 · Sale · Disposed 22,759 · Balance 4,812,221 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,732,894	Reported balance After 2017-11-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-11-06 · Sale · Disposed 79,327 · Balance 4,732,894 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,709,894	Reported balance After 2017-11-07 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-11-07 · Sale · Disposed 23,000 · Balance 4,709,894 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,693,019	Reported balance After 2017-11-08 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2017-11-08 · Sale · Disposed 16,875 · Balance 4,693,019 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,673,019	Reported balance After 2017-11-09 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2017-11-09 · Sale · Disposed 20,000 · Balance 4,673,019 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,663,019	Reported balance After 2017-11-10 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2017-11-10 · Sale · Disposed 10,000 · Balance 4,663,019 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,597,926	Reported balance After 2017-11-13 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2017-11-13 · Sale · Disposed 65,093 · Balance 4,597,926 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,583,019	Reported balance After 2017-11-14 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2017-11-14 · Sale · Disposed 14,907 · Balance 4,583,019 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,568,019	Reported balance After 2017-11-15 transaction · row 9 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 9 · 2017-11-15 · Sale · Disposed 15,000 · Balance 4,568,019 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,463,019	Reported balance After 2017-11-16 transaction · row 10 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 10 · 2017-11-16 · Sale · Disposed 105,000 · Balance 4,463,019 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,411,737	Reported balance After 2017-11-17 transaction · row 11 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 11 · 2017-11-17 · Sale · Disposed 51,282 · Balance 4,411,737 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,253,019	Reported balance After 2017-11-20 transaction · row 12 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 12 · 2017-11-20 · Sale · Disposed 158,718 · Balance 4,253,019 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	4,173,019	Reported balance After 2018-11-21 transaction · row 13 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 13 · 2018-11-21 · Sale · Disposed 80,000 · Balance 4,173,019 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	3,917,019	Reported balance After 2017-11-22 transaction · row 14 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 14 · 2017-11-22 · Sale · Disposed 256,000 · Balance 3,917,019 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	3,891,009	Reported balance After 2017-11-24 transaction · row 15 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 15 · 2017-11-24 · Sale · Disposed 26,010 · Balance 3,891,009 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	3,863,019	Reported balance After 2017-11-27 transaction · row 16 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 16 · 2017-11-27 · Sale · Disposed 27,990 · Balance 3,863,019 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	3,857,939	Reported balance After 2017-11-28 transaction · row 17 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 17 · 2017-11-28 · Sale · Disposed 5,080 · Balance 3,857,939 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	3,853,676	Reported balance After 2017-11-29 transaction · row 18 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 18 · 2017-11-29 · Sale · Disposed 4,263 · Balance 3,853,676 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	3,841,010	Reported balance After 2017-11-30 transaction · row 19 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 19 · 2017-11-30 · Sale · Disposed 12,666 · Balance 3,841,010 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	3,753,019	Reported balance After 2017-12-01 transaction · row 20 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 20 · 2017-12-01 · Sale · Disposed 87,991 · Balance 3,753,019 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee explanation of responses	3,722,534	Reported balance After 2017-12-04 transaction · row 21 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 21 · 2017-12-04 · Sale · Disposed 30,485 · Balance 3,722,534 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

SUTRO BIOPHARMA, INC.

Report date October 01, 2018 · Filed October 02, 2018

Section 16 reporting ended · disclosed 2018-10-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,726,197	Reported balance After 2018-10-01 transaction · row 1 1 source row Row 1 · 2018-10-01 · Conversion · Acquired 1,726,197 · Balance 1,726,197 F1: Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. F2: Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. F3: Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date. F4: Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date.
Series C-2 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-10-01 · Conversion · Disposed 8,338,892 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date.
Series D Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-10-01 · Conversion · Disposed 2,845,114 · Balance 0 F2: Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date.
Series D-2 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-10-01 · Conversion · Disposed 18,097,331 · Balance 0 F3: Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date.
Series E Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-10-01 · Conversion · Disposed 18,726,075 · Balance 0 F4: Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date.

F2: Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date.

F3: Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date.

F4: Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 09, 2020 Filed Jul 13, 2020 22:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherOption Warrant · Derivative	38,979	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0001104659-20-083172 · tm2024764-1_4.xml · derivative · entry 3 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value · 38,979 shares Expires 2020-07-09 F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
July 09, 2020 Filed Jul 13, 2020 22:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	2,241	$102.28	$229,209.48	Disclosure SEC source: 0001104659-20-083172 · tm2024764-1_4.xml · nonDerivative · entry 2 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,008,510 F3 · kind: On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares. Read SEC document
July 09, 2020 Filed Jul 13, 2020 22:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	38,979	$5.88	$229,196.52	Disclosure SEC source: 0001104659-20-083172 · tm2024764-1_4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,010,751 F1 · ownership.direct: This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the "Reporting Persons"). F2 · ownership.direct: These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities. Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:24 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	PurchaseCommon Stock	108,108	$92.50	$9,999,990.00	Disclosure SEC source: 0001104659-20-081337 · tm2024196-2_4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,971,772 F1 · ownership.direct: This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company. F2 · ownership.direct: These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities. Read SEC document
November 12, 2019 Filed Nov 14, 2019 16:06 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	PurchaseCommon Stock	403,225	$31.00	$12,499,975.00	Disclosure SEC source: 0001104659-19-064171 · tm1922788d1_4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777,824 Read SEC document
January 18, 2019 Filed Jan 22, 2019 17:00 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	PurchaseCommon Stock	706,206	$43.00	$30,366,858.00	Disclosure SEC source: 0001415889-19-000088 · form4-01222019_050101.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,824,685 Read SEC document
November 21, 2018 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	80,000	$19.25	$1,540,000.00	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 13 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,173,019 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
October 01, 2018 Filed Oct 2, 2018 16:10 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries E Redeemable Convertible Preferred Stock · Derivative	18,726,075	$0.00	$0.00	Disclosure SEC source: 0001415889-18-001458 · form4-10022018_011020.xml · derivative · entry 5 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 514,967 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date. F4 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date. F4 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date. Read SEC document
October 01, 2018 Filed Oct 2, 2018 16:10 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries D-2 Redeemable Convertible Preferred Stock · Derivative	18,097,331	$0.00	$0.00	Disclosure SEC source: 0001415889-18-001458 · form4-10022018_011020.xml · derivative · entry 4 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 758,278 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date. Read SEC document
October 01, 2018 Filed Oct 2, 2018 16:10 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries D Redeemable Convertible Preferred Stock · Derivative	2,845,114	$0.00	$0.00	Disclosure SEC source: 0001415889-18-001458 · form4-10022018_011020.xml · derivative · entry 3 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. Read SEC document
October 01, 2018 Filed Oct 2, 2018 16:10 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries C-2 Redeemable Convertible Preferred Stock · Derivative	8,338,892	$0.00	$0.00	Disclosure SEC source: 0001415889-18-001458 · form4-10022018_011020.xml · derivative · entry 2 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 337,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. Read SEC document
October 01, 2018 Filed Oct 2, 2018 16:10 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	1,726,197	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-18-001458 · form4-10022018_011020.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,726,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. F2 · price: Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date. F3 · price: Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date. F4 · price: Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date. Read SEC document
January 23, 2018 Filed Jan 23, 2018 16:35 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	PurchaseCommon Stock	851,154	$67.00	$57,027,318.00	Disclosure SEC source: 0001209191-18-004895 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,599 Read SEC document
January 23, 2018 Filed Jan 31, 2018 08:39 UTC Amendment	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	PurchaseCommon Stock	851,154	$67.00	$57,027,318.00	Disclosure SEC source: 0001209191-18-006131 · doc4a.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,599 F1 · date: This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018. Read SEC document
December 04, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	30,485	$19.47	$593,542.95	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 21 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,722,534 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
December 01, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	87,991	$19.10	$1,680,628.10	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 20 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,753,019 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 30, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	12,666	$19.04	$241,160.64	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 19 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,841,010 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 29, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	4,263	$19.25	$82,062.75	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 18 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,853,676 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 28, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	5,080	$19.22	$97,637.60	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 17 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,857,939 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 27, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	27,990	$19.75	$552,802.50	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 16 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,863,019 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 24, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	26,010	$20.00	$520,200.00	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 15 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,891,009 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 22, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	256,000	$19.76	$5,058,560.00	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 14 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,917,019 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 20, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	158,718	$19.02	$3,018,816.36	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 12 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,253,019 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 17, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	51,282	$18.44	$945,640.08	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 11 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,411,737 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 16, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	105,000	$18.39	$1,930,950.00	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 10 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,463,019 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 15, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	15,000	$17.67	$265,050.00	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 9 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,568,019 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 14, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	14,907	$17.19	$256,251.33	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 8 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,583,019 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 13, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	65,093	$17.76	$1,156,051.68	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 7 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,597,926 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 10, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	10,000	$17.28	$172,800.00	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 6 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,663,019 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 09, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	20,000	$17.08	$341,600.00	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 5 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,673,019 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 08, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	16,875	$18.06	$304,762.50	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 4 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,693,019 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 07, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	23,000	$18.54	$426,420.00	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 3 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,709,894 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 06, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	79,327	$18.89	$1,498,487.03	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 2 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,732,894 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
November 03, 2017 Filed Dec 7, 2017 09:57 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	22,759	$19.10	$434,696.90	Disclosure SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,812,221 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
September 25, 2017 Filed Sep 25, 2017 16:23 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	PurchaseCommon Stock	745,592	$37.00	$27,586,904.00	Disclosure SEC source: 0001209191-17-053822 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,118,479 Read SEC document
April 24, 2017 Filed Apr 24, 2017 16:34 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	PurchaseCommon Stock	624,575	$49.50	$30,916,462.50	Disclosure SEC source: 0001209191-17-027983 · doc4.xml · nonDerivative · entry 1 Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,856,353 F1 · ownership.nature: Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC ("Celgene Switzerland"), 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC ("Celgene Alpine"), each a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all such shares. Celgene and Celgene European Investment Company LLC, a wholly owned subsidiary of Celgene ("CEICO"), disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. The remaining 523,445 shares are owned directly by Celgene. CEICO, Celgene Switzerland and Celgene Alpine disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
April 11, 2017 Filed Apr 13, 2017 16:07 UTC	Adynxx, Inc. ALQA · Entity 155807	OtherCommon Stock	296,277	$0.00	$0.00	Disclosure SEC source: 0001209191-17-026849 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,342,377 F1 · kind: Pursuant to a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated February 27, 2017, with the Issuer, the Reporting Person purchased in a private placement (the "Private Placement") 4,000,000 shares of Common Stock at a purchase price of $0.50 per share (the "Per Share Purchase Price"). The Securities Purchase Agreement contains a "most-favored nation" provision that provides that if the Issuer, during 120 days from February 27, 2017, issues or sells any Common Stock or Common Stock equivalents reasonably believed to be more favorable in terms or conditions than the Private Placement, the Issuer must amend the terms of the Securities Purchase Agreement to give the Private Placement investors, including the Reporting Person, the benefit of such more favorable terms or conditions. F2 · kind: In accordance with this provision, effective as of April 11, 2017, following a public offering of Common Stock at a purchase price of $0.40 per share (the "Public Offering Price") on April 3, 2017, the Issuer adjusted the Per Share Purchase Price to the Public Offering Price, and is required to issue additional shares of Common Stock to the Private Placement investors, including the Reporting Person, which issuance is subject to stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market and certain side letter agreement, dated March 13, 2017, between the Issuer and the Reporting Person (the "Side Letter"). F3 · kind: Pursuant to the Securities Purchase Agreement and subject to the Side Letter, on April 11, 2017, the Issuer issued 296,277 shares of Common Stock to the Reporting Person (the "MFN Shares"), and will issue 703,723 additional shares of Common Stock to the Reporting Person if the Issuer obtains stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market. Read SEC document
February 27, 2017 Filed Mar 1, 2017 16:19 UTC	Adynxx, Inc. ALQA · Entity 155807	PurchaseCommon Stock	4,000,000	$0.50	$2,000,000.00	Disclosure SEC source: 0001209191-17-015840 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,046,100 Read SEC document
February 01, 2017 Filed Feb 1, 2017 16:18 UTC	Jounce Therapeutics, Inc. JNCE · Entity 15754	ConversionSeries B-1 Preferred Stock · Derivative	10,448,100	$0.00	$0.00	Disclosure SEC source: 0001209191-17-006676 · doc4.xml · derivative · entry 3 Celgene Switzerland LLC · CIK 0001661486 · 10% owner CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,831,463 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document
February 01, 2017 Filed Feb 1, 2017 16:18 UTC	Jounce Therapeutics, Inc. JNCE · Entity 15754	PurchaseCommon Stock	625,000	$16.00	$10,000,000.00	Disclosure SEC source: 0001209191-17-006676 · doc4.xml · nonDerivative · entry 2 Celgene Switzerland LLC · CIK 0001661486 · 10% owner CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,456,463 F2 · ownership.direct: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document
February 01, 2017 Filed Feb 1, 2017 16:18 UTC	Jounce Therapeutics, Inc. JNCE · Entity 15754	ConversionCommon Stock	2,831,463	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-006676 · doc4.xml · nonDerivative · entry 1 Celgene Switzerland LLC · CIK 0001661486 · 10% owner CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,831,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date. F2 · ownership.direct: These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document
October 24, 2016 Filed Oct 26, 2016 16:15 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries B Preferred Shares · Derivative	4,034,830	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-16-146978 · doc4.xml · derivative · entry 3 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,034,830 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. F2 · ownership.direct: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.direct: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
October 24, 2016 Filed Oct 26, 2016 16:15 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Stock	800,150	$14.00	$11,202,100.00	Disclosure SEC source: 0001209191-16-146978 · doc4.xml · nonDerivative · entry 2 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,834,980 F2 · ownership.direct: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.direct: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
October 24, 2016 Filed Oct 26, 2016 16:15 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	4,034,830	$0.00	$0.00	Disclosure SEC source: 0001209191-16-146978 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,034,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.direct: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
October 24, 2016 Filed Oct 27, 2016 16:45 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionSeries B Preferred Shares · Derivative	4,034,830	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-16-147161 · doc4a.xml · derivative · entry 3 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Common Shares · 4,034,830 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
October 24, 2016 Filed Oct 27, 2016 16:45 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Stock	800,150	$14.00	$11,202,100.00	Disclosure SEC source: 0001209191-16-147161 · doc4a.xml · nonDerivative · entry 2 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 4,834,980 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document
October 24, 2016 Filed Oct 27, 2016 16:45 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	ConversionCommon Stock	4,034,830	$0.00	$0.00	Disclosure SEC source: 0001209191-16-147161 · doc4a.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 4,034,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.